SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG (RHHBY) on Thursday said its investigational drug divarasib demonstrated superior survival outcomes compared with first-generation KRAS G12C inhibitors sotorasib and adagrasib in the Phase III Krascendo-1 study involving patients with non-small cell lung cancer (NSCLC).
The trial evaluated divarasib, a KRAS G12C inhibitor, against sotorasib and adagrasib in previously treated patients with KRAS G12C-mutated NSCLC.
The study met its primary endpoint and key secondary endpoint, with divarasib delivering clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS).
Roche said divarasib's safety profile was consistent with previous studies, with no new safety signals identified. The most common treatment-related adverse events were manageable and reversible.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
